source
- Moderna and Merck report success for personalized mRNA vaccine in late-stage melanoma trialModerna and Merck announced that their personalized mRNA cancer vaccine succeeded in a late-stage melanoma study. The vaccine, called intismeran, was evaluated in a randomized Phase 3 trial, the fi…
- Study Finds Accelerated Approval Rarely Used for Adult Cancer Drugs Over Past 20 YearsA new analysis published in JAMA shows that most adult oncology medicines approved by the FDA in the last two decades received standard approvals for expanded uses, relying on surrogate endpoints r…